CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
The latest 13F from CHI Advisors LLC covers Q3 2023 (filed Nov 13, 2023): 26 long positions worth $252.1M. The top 10 holdings make up 81.4% of the portfolio, and the largest is Pliant Therapeutics, Inc. (PLRX) at 20.7%. Livermore has 12 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q3 2023
Share counts compared with Q2 2023: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 4
- Est. +$16.6M
- Added
- 8
- Est. +$21.5M
- Reduced
- 8
- Est. −$13.9M
- Sold out
- 3
- Est. −$48.1M
Top 5 holdings
Share of this quarter's portfolio value
Biggest buys
New and added positions, by estimated amount bought
Largest weight increases
New and added positions, by percentage points of the portfolio gained
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q3 2023, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $252.1M
- −$77.3M (−23.5%) vs. prior quarter
- Positions
- 26
- +1 vs. prior quarter
- Top 10 concentration
- 81.4%
- Top 10 as share of value
- Turnover
- 13.1%
- Q3 2023, one quarter
- Average holding period
- 8.1 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
11 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $499.5M (Q1 2021)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q3 2023 | Nov 13, 2023 | 26 | $252.1M | PLRXRPTXCGEM | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 22, 2023Amended | 25 | $329.4M | PLRXSLRNVectivbio Hldg AG | vs. Q1 2023 | SEC |
| Q1 2023 | May 11, 2023 | 23 | $376.6M | RXDXPLRXVectivbio Hldg AG | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 13, 2023 | 22 | $375.4M | RXDXPLRXVectivbio Hldg AG | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 9, 2022 | 25 | $371.9M | RXDXPLRXCGEM | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 12, 2022 | 25 | $261.5M | RXDXCGEMRPTX | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 21 | $235.0M | RXDXRPTXCGEM | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 11, 2022 | 20 | $301.3M | RXDXRPTXCGEM | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 19 | $342.6M | RXDXRPTXCGEM | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 11, 2021 | 18 | $429.9M | RPTXRXDXPLRX | vs. Q1 2021 | SEC |
| Q1 2021 | May 14, 2021 | 21 | $499.5M | CGEMPLRXRPTX | – | SEC |
13D and 13G filings
Companies where CHI Advisors LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
CHI Advisors LLC does not currently report owning 5% or more of any company.
Latest filings
22 filings on file made by CHI Advisors LLC or listing it as a reporting person; the latest 20 are shown.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| INZYInozyme Pharma, Inc. | Feb 13, 2023 | 13GOld format | – | New | – | SEC |
| VectivBio Holding AG | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| RPTXRepare Therapeutics Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| PLRXPliant Therapeutics, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| ORTXOrchard Therapeutics plc | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| ONCROncorus, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| LRMRLarimar Therapeutics, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| CRVSCorvus Pharmaceuticals, Inc. | Feb 13, 2023 | 13GOld format | – | New | – | SEC |
| Freeline Therapeutics Holdings plc | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| CGEMCullinan Therapeutics, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| ORTXOrchard Therapeutics plc | Feb 11, 2022 | 13GOld format | – | New | – | SEC |
| Freeline Therapeutics Holdings plc | Feb 11, 2022 | 13GOld format | – | New | – | SEC |
| VectivBio Holding AG | Feb 11, 2022 | 13GOld format | – | New | – | SEC |
| RPTXRepare Therapeutics Inc. | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| PLRXPliant Therapeutics, Inc. | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| ONCROncorus, Inc. | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| LRMRLarimar Therapeutics, Inc. | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| CGEMCullinan Therapeutics, Inc. | Feb 11, 2022 | 13GOld format | – | New | – | SEC |
| PLRXPliant Therapeutics, Inc. | Mar 2, 2021 | 13GOld format | – | New | – | SEC |
| RPTXRepare Therapeutics Inc. | Mar 2, 2021 | 13GOld format | – | New | – | SEC |